Dr. Reddy's Allots 4,110 Equity Shares Under ESOP Scheme
Dr. Reddy's Laboratories allotted 4,110 equity shares on August 26, 2026, to employees who exercised stock options under its ESOP Scheme, 2002. The allotment brings the total issued shares to 83,46,80,910, with a total share capital of ₹83,46,80,910.
The allotment of a small number of shares under an existing ESOP scheme is a standard corporate action with a negligible impact on the company's overall market capitalization or financial metrics.
The announcement is a routine update regarding the allotment of equity shares under an employee stock option scheme, which does not significantly impact the company's financial performance or strategic direction.
Dr. Reddy's Laboratories Limited announced the allotment of 4,110 equity shares of Re.1/- each, fully paid up, on August 26, 2026. This allotment was made to eligible employees who exercised their stock options under the Dr. Reddy’s Employees Stock Option Scheme, 2002.
The company has provided details as required under Regulation 10(c) of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. The equity shares issued are identical in all respects to existing shares and rank pari passu.
Following this allotment, the total issued shares of the company have increased to 83,46,80,910, with the total issued share capital amounting to ₹83,46,80,910/-. The exercise price per share was Re.1/-, with no premium.
The details submitted include the company's registered office address, the stock exchanges where its shares are listed (BSE Limited, National Stock Exchange of India Limited, New York Stock Exchange Inc., and NSE IFSC Limited), and confirmation that the schemes comply with SEBI regulations. The distinct numbers for the allotted shares range from 834675801 to 834679910, with an ISIN of INE089A01031.
What to do with a filing like this
Dr. Reddy's Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under other regulatory filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Dr. Reddy's Laboratories Limited. Read the original for the full detail.